A Prospective, Observational Study of HIV-Infected Pregnant Women and Their Infants at Clinical Sites in Latin American and Caribbean Countries

This study is currently recruiting participants.
Verified August 2013 by National Institutes of Health Clinical Center (CC)
Sponsor:
Information provided by:
National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier:
NCT00341302
First received: June 19, 2006
Last updated: March 14, 2014
Last verified: August 2013

June 19, 2006
March 14, 2014
July 2002
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00341302 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
A Prospective, Observational Study of HIV-Infected Pregnant Women and Their Infants at Clinical Sites in Latin American and Caribbean Countries
A Prospective, Observational Study of HIV-Infected Pregnant Women and HIV-Exposed, Uninfected Children at Clinical Sites in Latin American Countries

By the end of 1999, it was estimated that 1.2 million children were living with HIV infection. During 1999 alone, 600,000 children were newly infected with HIV, mostly in less-developed countries. Most HIV-infected children are infected by transmission from mother to child during pregnancy, at birth, or through breast milk. Antiretroviral medications, cesarean section before rupture of membranes, and avoidance of breastfeeding are ways to reduce the risk of transmission. This study will determine mother-to-child transmission rates and the effects on infants of exposure to antiretroviral medications and mode of delivery.

Approximately 180 to 240 HIV-infected pregnant women in Mexico and Argentina will be enrolled during the first year of this 5-year study. HIV-infected women will be evaluated during pregnancy, during delivery, and 6 months after delivery. At each visit, a history will be taken and physical examination given; blood will be collected for laboratory tests.

HIV-exposed infants will be evaluated through 6 months of age. At each of 2 visits, a history will be taken and physical examination given; blood will be collected for laboratory tests; and growth will be assessed.

This is an observational, prospective cohort study to describe the characteristics of HIV-infected pregnant women and their infants at participating clinical sites in Latin America and the Caribbean where formula and antiretroviral prophylaxis of mother-to-child transmission of HIV are available. We will describe the utilization of interventions related to decreasing the risk of mother-to-child transmission, including antiretroviral prophylaxis, cesarean section before labor and before ruptured membranes, and avoidance of breastfeeding. We will describe receipt of maternal antiretroviral therapies and determine mother-to-child HIV transmission rates. This study will describe maternal adverse events during pregnancy and the postpartum period. In addition, the study will describe infant outcomes potentially related to in utero and early infant exposure to antiretroviral medications and to mode of delivery. We will enroll approximately 180-240 HIV-infected pregnant women during the first year of this planned five-year study. HIV-infected women will be evaluated antepartum, intrapartum and six months postpartum. HIV-exposed infants will be evaluated through six months of age.

Observational
Not Provided
Not Provided
Not Provided
Not Provided
Not Provided
HIV
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
5000
Not Provided
Not Provided
  • INCLUSION CRITERIA: (HIV-Infected Pregnant Women)

Documentation of pregnancy, using one or more of the following:

Urine HCG pregnancy test;

Serum HCG pregnancy test;

Positive fetal heart tones by Doppler; or

Ultrasound.

Documentation of HIV infection, defined by any two of the following prior to or during pregnancy:

Reactive test for HIV antibody;

Positive HIV culture;

Positive HIV DNA PCR;

Positive neutralizable HIV p24 antigen;

Positive qualitative HIV RNA;

Quantitative HIV RNA greater than or equal to 1000 copies/ml; and

Diagnosis of AIDS-defining clinical condition.

Willingness and intent to deliver at the participating clinical site and to be followed through six months postpartum at the site or associated outpatient facility.

Willingness and ability to sign informed consent-Subject must be of an age to provide legal informed consent as defined by the country in which the subject resides.

Willingness and intent to have infant followed through six months of age.

Subjects may be co-enrolled in clinical trials for treatment or prophylaxis of HIV infection, opportunistic infections, or other HIV related problems.

Subjects may be re-enrolled with subsequent pregnancies during the study.

Subjects may enroll up to and prior to delivery, including during labor.

EXCLUSION CRITERIA: (HIV-Infected Pregnant Women)

Failure to meet inclusion criteria.

Female
Not Provided
No
Contact: George K Siberry, M.D. (301) 496-7350 siberryg@mail.nih.gov
Argentina,   Brazil,   Peru
 
NCT00341302
999902261, 02-CH-N261
Not Provided
Not Provided
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Not Provided
Principal Investigator: George K Siberry, M.D. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
National Institutes of Health Clinical Center (CC)
August 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP